Journal of Modern Oncology
ISSN 1815-1434 (Print)
ISSN 1815-1442 (Online)
Menu
Archives
Home
About the Journal
Editorial Policies
Author Guidelines
About the Journal
Issues
Search
Current
Archives
Contact
Editorial board
OmniDoctor
All Journals
User
Username
Password
Remember me
Forgot password?
Register
Search
Search
Search Scope
All
Authors
Title
Abstract
Index terms
Full Text
Browse
By Issue
By Author
By Title
Other Journals
×
User
Username
Password
Remember me
Forgot password?
Register
Search
Search
Search Scope
All
Authors
Title
Abstract
Index terms
Full Text
Browse
By Issue
By Author
By Title
Other Journals
Home
>
Search
>
Author Details
Author Details
Ganshina, Inna
Issue
Section
Title
File
Vol 22, No 2 (2020)
Best Practice
Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience
(Rus)
(Eng)
Vol 23, No 1 (2021)
CLINICAL ONCOLOGY
Opportunities for metastatic triple negative breast cancer therapy
(Rus)
Vol 22, No 4 (2020)
CLINICAL ONCOLOGY
The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
(Rus)
Vol 22, No 4 (2020)
CLINICAL ONCOLOGY
Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
(Rus)
Vol 22, No 4 (2020)
CLINICAL ONCOLOGY
Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor
(Rus)
Vol 23, No 1 (2021)
CLINICAL ONCOLOGY
Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice
(Rus)
(Eng)
Vol 23, No 1 (2021)
CLINICAL ONCOLOGY
Antiangiogenic therapy for breast cancer with triple negative phenotype
(Rus)
Vol 23, No 4 (2021)
CLINICAL ONCOLOGY
The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
(Rus)
Vol 23, No 4 (2021)
CLINICAL ONCOLOGY
Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III
(Rus)
Vol 26, No 1 (2024)
Articles
Safety and efficacy of ribociclib in combination with letrozole in an extended population of patients with HR+/HER2- advanced breast cancer: analysis of data from a subgroup of patients from Russia in the phase lllb CompLEEment-1 study
(Rus)
This website uses cookies
You consent to our cookies if you continue to use our website.
About Cookies
TOP